Bank of New York Mellon’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.18M | Buy |
454,115
+74,742
| +20% | +$328K | ﹤0.01% | 2904 |
|
|
2026
Q1 | $1.71M | Sell |
379,373
-8,541
| -2% | -$37.3K | ﹤0.01% | 2892 |
|
|
2025
Q4 | $1.87M | Sell |
387,914
-11,234
| -3% | -$50.5K | ﹤0.01% | 2878 |
|
|
2025
Q3 | $1.81M | Buy |
399,148
+32,796
| +9% | +$120K | ﹤0.01% | 2849 |
|
|
2025
Q2 | $1.13M | Buy |
366,352
+17,555
| +5% | +$58.3K | ﹤0.01% | 3068 |
|
|
2025
Q1 | $1.22M | Sell |
348,797
-4,577
| -1% | -$15.3K | ﹤0.01% | 2944 |
|
|
2024
Q4 | $1.16M | Buy |
353,374
+803
| +0.2% | +$2.95K | ﹤0.01% | 3062 |
|
|
2024
Q3 | $1.36M | Sell |
352,571
-141,158
| -29% | -$541K | ﹤0.01% | 2963 |
|
|
2024
Q2 | $1.53M | Buy |
493,729
+86,104
| +21% | +$258K | ﹤0.01% | 2949 |
|
|
2024
Q1 | $1.05M | Sell |
407,625
-49,203
| -11% | -$127K | ﹤0.01% | 3127 |
|
|
2023
Q4 | $1.14M | Buy |
456,828
+5,361
| +1% | +$10.5K | ﹤0.01% | 3120 |
|
|
2023
Q3 | $916K | Buy |
451,467
+850
| +0.2% | +$1.78K | ﹤0.01% | 3206 |
|
|
2023
Q2 | $1.04M | Buy |
450,617
+27,936
| +7% | +$72.7K | ﹤0.01% | 3180 |
|
|
2023
Q1 | $1.28M | Buy |
422,681
+4,154
| +1% | +$11.7K | ﹤0.01% | 3033 |
|
|
2022
Q4 | $975K | Buy |
418,527
+33,066
| +9% | +$79.1K | ﹤0.01% | 3202 |
|
|
2022
Q3 | $736K | Buy |
385,461
+30,612
| +9% | +$72.1K | ﹤0.01% | 3358 |
|
|
2022
Q2 | $962K | Sell |
354,849
-12,340
| -3% | -$31.6K | ﹤0.01% | 3233 |
|
|
2022
Q1 | $1.09M | Buy |
367,189
+14,236
| +4% | +$43.6K | ﹤0.01% | 3252 |
|
|
2021
Q4 | $1.37M | Buy |
352,953
+96,032
| +37% | +$373K | ﹤0.01% | 3203 |
|
|
2021
Q3 | $1.1M | Buy |
256,921
+16,929
| +7% | +$56.4K | ﹤0.01% | 3337 |
|
|
2021
Q2 | $727K | Buy |
239,992
+188,576
| +367% | +$584K | ﹤0.01% | 3590 |
|
|
2021
Q1 | $171K | Sell |
51,416
-4,898
| -9% | -$18.9K | ﹤0.01% | 4094 |
|
|
2020
Q4 | $200K | Buy |
56,314
+38,577
| +217% | +$135K | ﹤0.01% | 3976 |
|
|
2020
Q3 | $56K | Buy |
+17,737
| New | +$53.9K | ﹤0.01% | 4009 |
|
|
2020
Q1 | – | Sell |
-256,327
| Closed | -$713K | – | 4098 |
|
|
2019
Q4 | $713K | Hold |
256,327
| – | – | ﹤0.01% | 3401 |
|
|
2019
Q3 | $391K | Buy |
+256,327
| New | +$442K | ﹤0.01% | 3681 |
|
|
2019
Q2 | – | Sell |
-97,968
| Closed | -$350K | – | 4207 |
|
|
2019
Q1 | $350K | Buy |
97,968
+5,686
| +6% | +$21.8K | ﹤0.01% | 3688 |
|
|
2018
Q4 | $353K | Sell |
92,282
-99,575
| -52% | -$490K | ﹤0.01% | 3645 |
|
|
2018
Q3 | $1.81M | Buy |
191,857
+108,398
| +130% | +$1.08M | ﹤0.01% | 2897 |
|
|
2018
Q2 | $609K | Buy |
+83,459
| New | +$497K | ﹤0.01% | 3531 |
|
Other funds holding ABUS
WSL
N
CP
FCH
LWA
CCA
Bank of New York Mellon's ABUS Position: Q2 2026 in Review
Bank of New York Mellon increased its Arbutus Biopharma (ABUS) stake by 20% in Q2 2026, buying an estimated $328K and bringing the position to 454,115 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2904.
Bank of New York Mellon first reported a position in ABUS in Q2 2018 and has held it in 30 quarters since. 69 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.
- Bank of New York Mellon held 454,115 shares of Arbutus Biopharma worth $2.18M as of Q2 2026.
- Bank of New York Mellon bought 74,742 Arbutus Biopharma shares in Q2 2026, an estimated $328K.
- Arbutus Biopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2904 holding.
- Bank of New York Mellon first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 30 quarters since.
- 69 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.